Key Highlights
• Shares traded at $76.50 pre-market, up 10.90% from the $68.98 prior close.
• Third-quarter Revenue of about $203 million rose 41% year over year.
• Adjusted EPS of $0.51 compared with an estimate of $0.27.
• Full-year 2026 revenue guidance was raised to $764 million to $774 million.
• Gross Margin was 58.5% for the quarter, or 61.1% excluding PAD Aviation.
TransMedics Group (NASDAQ:TMDX) shares were trading higher in pre-market activity on Friday, November 6, after the company reported record third-quarter 2026 results and raised its full-year revenue guidance. The Andover, Massachusetts-based company is a commercial-stage medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. Its Organ Care System is a portable platform that perfuses, optimizes and monitors donor organs in near-physiologic conditions.
The company pairs that technology with its National OCS Program, a turnkey service that bundles organ retrieval, aviation and ground logistics, and clinical support. It has also expanded into European air logistics through a strategic Investment in PAD Aviation. The company was founded in 1998 and is led by its founder and CEO, Waleed Hassanein.
Revenue Growth and Margin Profile
Third-quarter total revenue was about $203 million, up 41% year over year, or up 35% on an organic basis to $194 million. Product revenue was $113 million, up 29%, and service revenue was $90 million, up 60%, or up 43% excluding PAD Aviation. Liver and heart case volumes reached new highs despite the usual third-quarter seasonality and a 6% decline in U.S. deceased donor volume.
Gross margin was 58.5%, or 61.1% excluding PAD Aviation, with product margin at 79.2% and service margin at 32.2%. Adjusted Operating Income was $28.9 million, or 14.2% of revenue, and adjusted EPS was $0.51. Cash rose about $20 million sequentially to $493 million.
Guidance Increase and Growth Catalysts
Full-year 2026 revenue guidance was raised to $764 million to $774 million, which the company said represents 26% to 28% growth. The prior range was $737 million to $757 million. Excluding PAD Aviation, the range is $750 million to $760 million, and adjusted Operating Margin guidance remains 12.5% to 14%.
Growth catalysts include the Enhance Heart Part A trial, which enrolled 175 patients, with a PMA filing targeted for 2027. The Part B study of 600 patients and the de novo lung study of 450 patients, both with CHOPS control arms, are expected to become catalysts starting in the first quarter of 2027. The CHOPS 510(k) decision is targeted for the second half of 2027.
Watch List: Fourth-Quarter Flight Volumes and Margin Trajectory
The company acknowledged softer October flight volumes and expects a fourth-quarter recovery, based on its track record and growth in ground transport. Gross margin is expected to hold near current levels in the near term, and R&D should stay stable over the next few quarters. The company's listing data shows a market Capitalization of $2.39 billion, and 2027 guidance will come with fourth-quarter results.






Please wait processing your request...